Abstract
Introduction: Advanced cancers that did not respond to chemotherapy were once a death sentence, but now there are newer therapies utilizing the patient’s own immune system to fight cancer that are proving effective in chemotherapy-refractory malignancies. However, this success against cancer cells may be accompanied by immune-related adverse events that can affect the kidneys. Areas Covered: Using Medline and Scopus, we compiled all publications pertaining to ICPI and CAR T-cell therapy through February 2019. The focus of this review is discussion of two new cancer therapies, immune checkpoint inhibitors and chimeric antigen receptor T-cell therapy, with attention to the reported kidney-related adverse effects. Expert Opinion: Autoimmunity is repressed by molecular pathways that inhibit T-cell activation against selected antigens. These self-protective mechanisms have been appropriated by tumor cells as a means of evading immune detection and destruction. New immunotherapies such as immune checkpoint inhibitors and chimeric antigen receptor T-cell therapy incite an aggressive immune response directed against tumor cells. This unrestrained activation of the immune system may result in kidney injury via multiple mechanisms.

This publication has 92 references indexed in Scilit: